Ocular Therapeutix Highlights AXPAXLI SOL-1 Enrollment And Plans Repeat Dosing Study In Wet AMD; Announces 48-Week Data From HELIOS NPDR Study
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutix has enrolled 151 subjects in the SOL-1 pivotal study of AXPAXLI for wet AMD and plans a repeat dosing study (SOL-R). The 48-week HELIOS NPDR study results show significant improvement in patients treated with AXPAXLI.
June 13, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocular Therapeutix has made significant progress in its clinical trials for AXPAXLI, enrolling 151 subjects in the SOL-1 study for wet AMD and planning a repeat dosing study. The 48-week HELIOS NPDR study results are promising, showing significant improvement in patients.
The enrollment of 151 subjects in the SOL-1 study and the planning of a repeat dosing study indicate strong progress in Ocular Therapeutix's clinical trials. The positive 48-week results from the HELIOS NPDR study further support the potential efficacy of AXPAXLI, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100